Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
Drug Saf. 2021 Feb 2. DOI: 10.1007/s40264-020-01036-w
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Drug Saf. 2021 Feb 2. DOI: 10.1007/s40264-020-01036-w
Ann Rheum Dis. 2021 Jan 15:annrheumdis-2020-219213.
Mod Rheumatol 2021;26:1–16.
Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219214
Annals of the rheumatic diseases. 2021 Mar 1;80(3):312-20.
J Eur Acad Dermatol Venereol 2020;34:2809–2820.
Please click the links below to go to the CSF review of each paper
Rheumatology 2020; doi:10.1093/rheumatology/keaa576
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
Annals of the Rheumatic Diseases 05 August 2020 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.